Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis.
We demonstrated that intranasal granulocyte-macrophage colony-stimulating factor given to immunosuppressed mice infected with pulmonary aspergillosis resulted in a sixfold reduction in the lung fungal burden compared to the result for saline-treated mice (P = 0.045). These data suggest that lung-targeted immunotherapy may be complementary to antifungal agents and may improve patient responses.
Quezada
Gerardo
G
The Children's Cancer Hospital, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA.
Koshkina
Nadezhda V
NV
Zweidler-McKay
Patrick
P
Zhou
Zichao
Z
Kontoyiannis
Dimitrios P
DP
Kleinerman
Eugenie S
ES
D000281:Administration, Intranasal; D000818:Animals; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004195:Disease Models, Animal; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D051379:Mice; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide